Physician profile
Jossef Amirian
NPI 1144508557
$3,244.56
in general payments reported to CMS, 2019-2025
16 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $115 · 2021: $233 · 2022: $334 · 2023: $399 · 2024: $485 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $552.32 | 2019-2022 | |
| Medtronic Vascular, INC. | $521.59 | 2019-2020 | |
| Abiomed | $467.96 | 2019 | |
| Shockwave Medical, INC | $367.33 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $346.42 | 2023-2024 | Cg Future, Corevalve Evolut R |
| Cardiovascular Systems INC. | $230.06 | 2019 | |
| Philips North America LLC | $208.59 | 2019-2022 | |
| Amgen INC. | $161.96 | 2019-2025 | Repatha, Repatha |
| Terumo Medical Corporation | $96.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $95.32 | 2019-2024 | Eliquis |
| Lilly USA, LLC | $48.74 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $44.21 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $37.29 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $31.73 | 2024 | Opsumit, Uptravi |
| Baxter Healthcare | $20.29 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jossef Amirian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.